Aberrant Expression of the miR-181b/miR-222 after Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia
- 4 Downloads
Recently, dysregulated expression of various micro RNAs has been reported in hematologic malignancies, especially AML disease which affects normal hematopoiesis in these patients and thereby contribute to clinical outcome of AML patients, associated with either poor or favorable prognosis. Herein, we evaluated the expression of miR-181b and miR-222 in acute myeloid leukemia patients and correlation with response to therapy after hematopoietic stem cell transplantation. Eighty newly diagnosed AML patients and 80 healthy controls were recruited. The expression of miR-181b and miR-222 was evaluated by real-time SYBR Green PCR method. miR-181b gene expression was significantly increased (4.7 fold) whereas miR-222 was decreased (18.3 fold) in AML patients compared to controls (P = 0.03 and P < 0.001, respectively). Both miR-181b and miR-222 were not associated with response to treatment (P > 0.05). Also, miR-181b and miR-222 were not differentially expressed in AML patients with M3 compared to non-M3 FAB subtypes (P > 0.05). miR-181b and miR-222 are aberrantly expressed in AML patients and their baseline level is not associated with response to treatment.
KeywordsAcute myeloid leukemia (AML) miR-181b miR-222 Chemosensitivity
The authors would like to thanks, Dr. Nasrin Shokrpour at Center for Development of Clinical Research of Namazi Hospital for editorial assistance.
This study was financially supported by Shiraz University of Medical Sciences [Grant Number 94-01-104-11279].
Compliance with Ethical Standards
Conflict of interest
The authors declare that there is no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 8.Schwind S, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Whitman SP, Hickey C, Becker H, Metzeler KH (2010) Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 28(36):5257–5264CrossRefGoogle Scholar
- 10.Crossland RE, Norden J, Juric MK, Green K, Pearce KF, Lendrem C, Greinix HT, Dickinson AM (2017) Expression of serum micrornas is altered during acute graft-versus-host disease. Front Immunol 8:308Google Scholar
- 14.Mitelman F (1995) ISCN 1995: an international system for human cytogenetic nomenclature (1995): recommendations of the International Standing Committee on Human Cytogenetic Nomenclature, Memphis, Tennessee, USA, 9–13 Oct 1994. Karger Medical and Scientific PublishersGoogle Scholar
- 22.Gimondi S, Dugo M, Vendramin A, Bermema A, Biancon G, Cavané A, Corradini P, Carniti C (2016) Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation. Exp Hematol 44(7):624–634.e621CrossRefGoogle Scholar